• Amedisys Reports Third Quarter 2023 Financial Results

    来源: Nasdaq GlobeNewswire / 24 10月 2023 16:30:37   America/New_York

    BATON ROUGE, La., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2023.

    Three-Month Periods Ended September 30, 2023 and 2022

    • Net service revenue decreased $1.8 million to $556.2 million compared to $558.0 million in 2022. Prior year included $16.6 million of net service revenue from our personal care business which was divested on March 31, 2023.
    • Net income attributable to Amedisys, Inc. of $26.0 million compared to $25.6 million in 2022.
    • Net income attributable to Amedisys, Inc. per diluted share of $0.79 compared to $0.79 in 2022.

    Adjusted Quarterly Results*

    • Adjusted EBITDA of $57.9 million compared to $61.5 million in 2022.
    • Adjusted net service revenue of $556.2 million compared to $558.9 million in 2022. Prior year included $16.6 million of adjusted net service revenue from our personal care business which was divested on March 31, 2023.
    • Adjusted net income attributable to Amedisys, Inc. of $32.2 million compared to $37.4 million in 2022.
    • Adjusted net income attributable to Amedisys, Inc. per diluted share of $0.98 compared to $1.15 in 2022.

    Nine-Month Periods Ended September 30, 2023 and 2022

    • Net service revenue increased $4.5 million to $1,665.6 million compared to $1,661.1 million in 2022. Prior year included $30.5 million of incremental net service revenue from our personal care business which was divested on March 31, 2023.
    • Net loss attributable to Amedisys, Inc. of $29.1 million, which is inclusive of $131.2 million in costs associated with our merger transactions, compared to net income attributable to Amedisys, Inc. of $86.9 million in 2022.
    • Net loss attributable to Amedisys, Inc. per diluted share of $0.89 compared to net income attributable to Amedisys, Inc. per diluted share of $2.66 in 2022.

    Adjusted Year to Date Results*

    • Adjusted EBITDA of $190.4 million compared to $202.2 million in 2022.
    • Adjusted net service revenue of $1,665.6 million compared to $1,670.4 million in 2022. Prior year included $30.5 million of incremental adjusted net service revenue from our personal care business which was divested on March 31, 2023.
    • Adjusted net income attributable to Amedisys, Inc. of $109.8 million compared to $125.5 million in 2022.
    • Adjusted net income attributable to Amedisys, Inc. per diluted share of $3.36 compared to $3.84 in 2022.

    * See pages 2 and 14 - 16 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

    The supplemental slides provided in connection with the third quarter 2023 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the third quarter results.

    Non-GAAP Financial Measures

    This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income (loss) attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted net income attributable to Amedisys, Inc., defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items; and (4) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share calculated in accordance with GAAP excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

    Additional Information

    Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes, home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 18,600 employees in 521 care centers within 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 455,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

    We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

    Forward-Looking Statements

    When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19") on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

    Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

     

    Contact:Investor Contact:Media Contact:
     Amedisys, Inc.Amedisys, Inc.
     Nick MuscatoKendra Kimmons
     Chief Strategy OfficerVice President, Marketing & Communications
     (615) 928- 5452(225) 299-3720
     IR@amedisys.comkendra.kimmons@amedisys.com 


    AMEDISYS, INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Amounts in thousands, except per share data)
    (Unaudited)

     For the Three-Month 
    Periods Ended September 30,
     For the Nine-Month
    Periods Ended September 30,
      2023   2022   2023   2022 
    Net service revenue$556,237  $557,988  $1,665,594  $1,661,135 
    Operating expenses:       
    Cost of service, inclusive of depreciation 311,628   322,227   924,093   943,258 
    General and administrative expenses:       
    Salaries and benefits 129,083
       125,550   380,926
       376,788 
    Non-cash compensation 6,612
       3,495   18,968
       15,990 
    Merger-related expenses 4,980
          25,151
        
    Depreciation and amortization 4,436   5,477   13,604   19,705 
    Investment impairment    3,009      3,009 
    Other 57,287   59,299   180,467   167,851 
    Total operating expenses 514,026   519,057   1,543,209   1,526,601 
    Operating income 42,211   38,931   122,385   134,534 
    Other income (expense):       
    Interest income 1,304   59   2,452   108 
    Interest expense (8,021)  (4,963)  (23,040)  (16,447)
    Equity in earnings (loss) from equity method investments 1,252   302   9,366   (442)
    Merger termination fee       (106,000)   
    Miscellaneous, net 1,201   491   5,262   1,155 
    Total other expense, net (4,264)  (4,111)  (111,960)  (15,626)
    Income before income taxes 37,947   34,820   10,425   118,908 
    Income tax expense (12,331)  (9,417)  (40,381)  (32,755)
    Net income (loss) 25,616   25,403   (29,956)  86,153 
    Net loss attributable to noncontrolling interests 344   239   887   739 
    Net income (loss) attributable to Amedisys, Inc.$25,960  $25,642  $(29,069) $86,892 
    Basic earnings per common share:       
    Net income (loss) attributable to Amedisys, Inc. common stockholders$0.80  $0.79  $(0.89) $2.67 
    Weighted average shares outstanding 32,624   32,482   32,587   32,519 
    Diluted earnings per common share:       
    Net income (loss) attributable to Amedisys, Inc. common stockholders$0.79  $0.79  $(0.89) $2.66 
    Weighted average shares outstanding 32,831   32,616   32,587   32,680 


        AMEDISYS, INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (Amounts in thousands, except share data)

     September 30, 2023
    (unaudited)
     December 31, 2022
    ASSETS   
    Current assets:   
    Cash and cash equivalents$78,112  $40,540 
    Restricted cash 15,904   13,593 
    Patient accounts receivable 319,580   296,785 
    Prepaid expenses 20,534   11,628 
    Other current assets 33,097   26,415 
    Total current assets 467,227   388,961 
    Property and equipment, net of accumulated depreciation of $93,909 and $101,364 39,631   16,026 
    Operating lease right of use assets 87,834   102,856 
    Goodwill 1,244,679   1,287,399 
    Intangible assets, net of accumulated amortization of $12,838 and $14,604 103,634   101,167 
    Other assets 84,412   79,836 
    Total assets$2,027,417  $1,976,245 
    LIABILITIES AND EQUITY   
    Current liabilities:   
    Accounts payable$34,555  $43,735 
    Payroll and employee benefits 126,989   125,387 
    Accrued expenses 139,100   137,390 
    Termination fee paid by UnitedHealth Group 106,000    
    Current portion of long-term obligations 35,364   15,496 
    Current portion of operating lease liabilities 26,111   33,521 
    Total current liabilities 468,119   355,529 
    Long-term obligations, less current portion 366,853   419,420 
    Operating lease liabilities, less current portion 61,878   69,504 
    Deferred income tax liabilities 35,398   20,411 
    Other long-term obligations 1,651   4,808 
    Total liabilities 933,899   869,672 
    Equity:   
    Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding     
    Common stock, $0.001 par value, 60,000,000 shares authorized; 38,065,853 and 37,891,186 shares issued; 32,633,599 and 32,511,465 shares outstanding 38   38 
    Additional paid-in capital 776,880   755,063 
    Treasury stock, at cost, 5,432,254 and 5,379,721 shares of common stock (465,613)  (461,200)
    Retained earnings 728,603   757,672 
    Total Amedisys, Inc. stockholders’ equity 1,039,908   1,051,573 
    Noncontrolling interests 53,610   55,000 
    Total equity 1,093,518   1,106,573 
    Total liabilities and equity$2,027,417  $1,976,245 

     

    AMEDISYS, INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
    (Amounts in thousands, except statistical information)
    (Unaudited)

     For the Three-Month
    Periods Ended September 30,
     For the Nine-Month
    Periods Ended September 30,
      2023   2022   2023   2022 
    Cash Flows from Operating Activities:       
    Net income (loss)$25,616  $25,403  $(29,956) $86,153 
    Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:       
    Depreciation and amortization (inclusive of depreciation included in cost of service) 6,063   5,477   17,956   19,705 
    Non-cash compensation 7,243   3,495   19,624   15,990 
    Amortization and impairment of operating lease right of use assets 8,456   12,319   25,427   34,782 
    (Gain) loss on disposal of property and equipment (10)  (24)  346   507 
    Loss on personal care divestiture       2,186    
    Merger termination fee       106,000    
    Deferred income taxes 7,313   13,028   15,417   19,031 
    Equity in (earnings) loss from equity method investments (1,252)  (302)  (9,366)  442 
    Amortization of deferred debt issuance costs 248   248   743   743 
    Return on equity method investments 1,556   1,370   4,309   3,798 
    Investment impairment    3,009      3,009 
    Changes in operating assets and liabilities, net of impact of acquisitions:       
    Patient accounts receivable (40,796)  3,078   (32,934)  (18,266)
    Other current assets (17,123)  (15,461)  (15,434)  (19,929)
    Operating lease right of use assets (866)  (661)  (2,803)  (2,323)
    Other assets 29   63   273   283 
    Accounts payable (4,108)  1,388   (8,839)  5,886 
    Accrued expenses 5,565   (56,319)  10,340   (26,790)
    Other long-term obligations 23   466   (3,156)  243 
    Operating lease liabilities (7,800)  (10,207)  (23,256)  (30,864)
    Net cash (used in) provided by operating activities (9,843)  (13,630)  76,877   92,400 
    Cash Flows from Investing Activities:       
    Proceeds from the sale of deferred compensation plan assets    61   25   89 
    Proceeds from the sale of property and equipment    29   100   66 
    Purchases of property and equipment (984)  (1,556)  (3,728)  (4,338)
    Investments in technology assets (214)  (289)  (6,881)  (848)
    Investment in equity method investee    (637)     (637)
    Purchase of cost method investment          (15,000)
    Return of investment 150      150    
    Proceeds from personal care divestiture       47,787    
    Acquisitions of businesses, net of cash acquired    1,359   (350)  (71,952)
    Net cash (used in) provided by investing activities (1,048)  (1,033)  37,103   (92,620)
    Cash Flows from Financing Activities:       
    Proceeds from issuance of stock upon exercise of stock options 25   306   100   1,078 
    Proceeds from issuance of stock under employee stock purchase plan 848   966   2,602   2,857 
    Shares withheld to pay taxes on non-cash compensation (925)  (3,187)  (4,413)  (7,949)
    Noncontrolling interest contributions 856   1,148   1,232   2,100 
    Noncontrolling interest distributions (902)  (450)  (1,614)  (1,425)
    Proceeds from sale of noncontrolling interest    3,941      3,941 
    Proceeds from borrowings under revolving line of credit    185,500   23,000   484,000 
    Repayments of borrowings under revolving line of credit    (182,000)  (23,000)  (465,500)
    Principal payments of long-term obligations (6,120)  (3,151)  (67,113)  (10,126)
    Purchase of company stock          (17,351)
    Payment of accrued contingent consideration (36)  (5,714)  (4,091)  (5,714)
    Purchase of noncontrolling interest       (800)   
    Net cash used in financing activities (6,254)  (2,641)  (74,097)  (14,089)
    Net (decrease) increase in cash, cash equivalents and restricted cash (17,145)  (17,304)  39,883   (14,309)
    Cash, cash equivalents and restricted cash at beginning of period 111,161   48,764   54,133   45,769 
    Cash, cash equivalents and restricted cash at end of period$94,016  $31,460  $94,016  $        31,460 
            
     For the Three-Month 
    Periods Ended September 30,
     For the Nine-Month 
    Periods Ended September 30,
      2023   2022   2023   2022 
    Supplemental Disclosures of Cash Flow Information:       
    Cash paid for interest$6,756  $4,664  $19,787  $9,153 
    Cash paid for Infinity ZPIC interest$  $11,544  $  $11,544 
    Cash paid for income taxes, net of refunds received$8,498  $605  $24,318  $23,582 
    Cash paid for operating lease liabilities$8,665  $10,868  $26,059  $33,187 
    Cash paid for finance lease liabilities$3,141  $339  $8,462  $1,074 
    Supplemental Disclosures of Non-Cash Activity:       
    Right of use assets obtained in exchange for operating lease liabilities$10,459  $10,390  $25,261  $36,980 
    Right of use assets obtained in exchange for finance lease liabilities$7,020  $530  $34,964  $1,846 
    Reductions to right of use assets resulting from reductions to operating lease liabilities$  $624  $15,135  $3,387 
    Reductions to right of use assets resulting from reductions to finance lease liabilities$315  $564  $1,209  $564 
    Accrued contingent consideration$  $  $  $19,195 
    Noncontrolling interest contribution$  $  $  $8,900 
    Days revenue outstanding (1) 49.8   47.3   49.8   47.3 


    (1)Our calculation of days revenue outstanding at September 30, 2023 and 2022 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended September 30, 2023 and 2022, respectively.


    AMEDISYS, INC. AND SUBSIDIARIES
    SEGMENT INFORMATION
    (Amounts in millions, except statistical information)
    (Unaudited)

    Segment Information - Home Health

     For the Three-Month Periods
    Ended September 30,
      2023   2022 
    Financial Information (in millions) (6):   
    Medicare$217.9  $225.6 
    Non-Medicare 133.7   113.6 
    Net service revenue 351.6   339.2 
    Cost of service, inclusive of depreciation 201.6   196.7 
    Gross margin 150.0   142.5 
    General and administrative expenses 91.4   89.1 
    Depreciation and amortization 1.8   0.9 
    Operating income$56.8  $52.5 
    Same Store Growth(1):   
    Medicare revenue (2%)  (6%)
    Non-Medicare revenue 17%  (1%)
    Total admissions 4%  5%
    Total volume(2) 3%  1%
    Key Statistical Data - Total(3)(6):   
    Admissions 98,527   95,566 
    Recertifications 45,693   45,098 
    Total volume 144,220   140,664 
        
    Medicare completed episodes 72,714   76,334 
    Average Medicare revenue per completed episode(4)$3,015  $2,992 
    Medicare visits per completed episode(5) 12.4   12.7 
        
    Visiting clinician cost per visit$105.06  $101.33 
    Clinical manager cost per visit 11.98   11.44 
    Total cost per visit$117.04  $112.77 
    Visits 1,723,289   1,744,385 


     For the Nine-Month Periods
    Ended September 30,
      2023   2022 
    Financial Information (in millions) (6):   
    Medicare$653.1  $671.7 
    Non-Medicare 391.6   345.1 
    Net service revenue 1,044.7   1,016.8 
    Cost of service, inclusive of depreciation 593.1   576.6 
    Gross margin 451.6   440.2 
    General and administrative expenses 270.5   261.1 
    Depreciation and amortization 4.3   3.3 
    Operating income$176.8  $175.8 
    Same Store Growth(1):   
    Medicare revenue (3%)  (5%)
    Non-Medicare revenue 13%  %
    Total admissions 5%  2%
    Total volume(2) 3%  %
    Key Statistical Data - Total(3)(6):   
    Admissions 297,943   281,393 
    Recertifications 134,826   133,775 
    Total volume 432,769   415,168 
        
    Medicare completed episodes 221,125   229,098 
    Average Medicare revenue per completed episode(4)$2,998  $3,019 
    Medicare visits per completed episode(5) 12.4   13.0 
        
    Visiting clinician cost per visit$101.55  $98.72 
    Clinical manager cost per visit 11.41   10.99 
    Total cost per visit$112.96  $109.71 
    Visits 5,250,944   5,256,207 


    (1)Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
    (2)Total volume includes all admissions and recertifications.
    (3)Total includes acquisitions, startups and de novos.
    (4)Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration at 2% and 1% for the three-month periods ended March 31, 2022 and June 30, 2022, respectively, and the reinstatement of sequestration at 2% effective July 1, 2022.
    (5)Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
    (6)Prior year has been recast to conform to the current year presentation.


    Segment Information - Hospice

     For the Three-Month Periods
    Ended September 30,
      2023   2022 
    Financial Information (in millions):   
    Medicare$188.9  $187.8 
    Non-Medicare 11.3   10.9 
    Net service revenue 200.2   198.7 
    Cost of service, inclusive of depreciation 104.2   109.4 
    Gross margin 96.0   89.3 
    General and administrative expenses 48.4   49.1 
    Depreciation and amortization 0.8   0.5 
    Operating income$46.8  $39.7 
    Same Store Growth(1):   
    Medicare revenue 1%  %
    Hospice admissions (6%)  (3%)
    Average daily census (2%)  1%
    Key Statistical Data - Total(2):   
    Hospice admissions 11,968   12,782 
    Average daily census 12,943   13,314 
    Revenue per day, net$168.11  $162.24 
    Cost of service per day$87.48  $89.36 
    Average discharge length of stay 94   92 


     For the Nine-Month Periods
    Ended September 30,
      2023   2022 
    Financial Information (in millions):   
    Medicare$559.8  $557.8 
    Non-Medicare 33.0   32.4 
    Net service revenue 592.8   590.2 
    Cost of service, inclusive of depreciation 304.4   323.2 
    Gross margin 288.4   267.0 
    General and administrative expenses 144.1   152.1 
    Depreciation and amortization 2.2   1.7 
    Operating income$142.1  $113.2 
    Same Store Growth(1):   
    Medicare revenue %  %
    Hospice admissions (6%)  1%
    Average daily census (2%)  (1%)
    Key Statistical Data - Total(2):   
    Hospice admissions 37,361   40,027 
    Average daily census 12,864   13,163 
    Revenue per day, net$168.80  $164.24 
    Cost of service per day$86.66  $89.94 
    Average discharge length of stay 91   90 


    (1)Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
    (2)Total includes acquisitions and de novos.


    Segment Information - Personal Care (1)

     For the Three-Month Periods
    Ended September 30,
      2023  2022
    Financial Information (in millions):   
    Medicare$ $
    Non-Medicare   16.6
    Net service revenue   16.6
    Cost of service, inclusive of depreciation   12.2
    Gross margin   4.4
    General and administrative expenses   2.4
    Depreciation and amortization   
    Operating income$ $2.0
    Key Statistical Data - Total:   
    Billable hours   474,365
    Clients served   7,771
    Shifts   202,638
    Revenue per hour$ $34.98
    Revenue per shift$ $81.89
    Hours per shift   2.3


     For the Nine-Month Periods
    Ended September 30,
      2023  2022
    Financial Information (in millions):   
    Medicare$ $
    Non-Medicare 15.0  45.5
    Net service revenue 15.0  45.5
    Cost of service, inclusive of depreciation 11.1  34.5
    Gross margin 3.9  11.0
    General and administrative expenses 2.3  6.8
    Depreciation and amortization   0.1
    Operating income$1.6 $4.1
    Key Statistical Data - Total:   
    Billable hours 440,464  1,397,919
    Clients served 7,892  9,530
    Shifts 191,379  598,376
    Revenue per hour$33.97 $32.53
    Revenue per shift$78.19 $76.00
    Hours per shift 2.3  2.3


    (1)We completed the sale of our personal care business on March 31, 2023.


    Segment Information - High Acuity Care

     For the Three-Month Periods
    Ended September 30,
      2023   2022 
    Financial Information (in millions) (1):   
    Medicare$  $ 
    Non-Medicare 4.4   3.5 
    Net service revenue 4.4   3.5 
    Cost of service, inclusive of depreciation 5.8   3.9 
    Gross margin (1.4)  (0.4)
    General and administrative expenses 5.3   5.2 
    Depreciation and amortization 0.7   0.8 
    Investment impairment    3.0 
    Operating loss$(7.4) $(9.4)
    Key Statistical Data - Total:   
    Full risk admissions 150   130 
    Limited risk admissions 430   300 
    Total admissions 580   430 
        
    Full risk revenue per episode$10,168  $11,615 
    Limited risk revenue per episode$6,242  $5,580 
        
    Number of admitting joint venture markets 11   8 


     For the Nine-Month Periods
    Ended September 30,
      2023   2022 
    Financial Information (in millions) (1):   
    Medicare$  $   — 
    Non-Medicare 13.1   8.6 
    Net service revenue 13.1   8.6 
    Cost of service, inclusive of depreciation 15.5   9.0 
    Gross margin (2.4)  (0.4)
    General and administrative expenses 15.0   14.6 
    Depreciation and amortization 2.3   2.4 
    Investment impairment    3.0 
    Operating loss$(19.7) $(20.4)
    Key Statistical Data - Total:   
    Full risk admissions 468   339 
    Limited risk admissions 1,263   768 
    Total admissions 1,731   1,107 
        
    Full risk revenue per episode$10,783  $11,018 
    Limited risk revenue per episode$5,881  $5,556 
        
    Number of admitting joint venture markets 11   8 


    (1)Prior year has been recast to conform to the current year presentation.


    Segment Information - Corporate

     For the Three-Month Periods
    Ended September 30,
      2023  2022
    Financial Information (in millions) (1):   
    General and administrative expenses$52.9 $42.6
    Depreciation and amortization 1.1  3.3
    Total operating expenses$54.0 $45.9


     For the Nine-Month Periods
    Ended September 30,
      2023  2022
    Financial Information (in millions) (1):   
    General and administrative expenses$173.6 $126.0
    Depreciation and amortization 4.8  12.2
    Total operating expenses$178.4 $138.2


    (1)Prior year has been recast to conform to the current year presentation.


        AMEDISYS, INC. AND SUBSIDIARIES
    RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
    (Amounts in thousands)
    (Unaudited)

    Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:
     For the Three-Month Periods
    Ended September 30,
     For the Nine-Month Periods
    Ended September 30,
      2023  2022  2023   2022 
    Net income (loss) attributable to Amedisys, Inc.$25,960 $25,642 $(29,069) $86,892 
    Add:       
    Income tax expense 12,331  9,417  40,381   32,755 
    Interest expense, net 6,717  4,904  20,588   16,339 
    Depreciation and amortization 6,063  5,477  17,956   19,705 
    Certain items(1) 6,807  15,861  140,498   50,920 
    Interest component of certain items(1)   207     (4,445)
    Adjusted EBITDA(2)(6)$57,878 $61,508 $190,354  $202,166 


    Adjusted Net Service Revenue Reconciliation:

     For the Three-Month Periods
    Ended September 30,
     For the Nine-Month Periods
    Ended September 30,
      2023  2022  2023  2022
    Net service revenue$556,237 $557,988 $1,665,594 $1,661,135
    Add:       
    Certain items(1)   931    9,305
    Adjusted net service revenue(3) (6)$556,237 $558,919 $1,665,594 $1,670,440


    Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:

     For the Three-Month Periods
    Ended September 30,
     For the Nine-Month Periods
    Ended September 30,
      2023  2022  2023   2022
    Net income (loss) attributable to Amedisys, Inc.$25,960 $25,642 $(29,069) $86,892
    Add:       
    Certain items(1) 6,242  11,740  138,884   38,587
    Adjusted net income attributable to Amedisys, Inc.(4)(6)$32,202 $37,382 $109,815  $125,479


    Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:

     For the Three-Month Periods
    Ended September 30,
     For the Nine-Month Periods
    Ended September 30,
      2023  2022  2023   2022
    Net income (loss) attributable to Amedisys, Inc. common stockholders per diluted share$0.79 $0.79 $(0.89) $2.66
    Add:       
    Certain items(1) 0.19  0.36  4.25   1.18
    Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(5)(6)$0.98 $1.15 $3.36  $3.84


    (1)The following details the certain items for the three and nine-month periods ended September 30, 2023 and 2022:


    Certain Items (in thousands):

     For the Three-Month Periods
    Ended September 30, 2023
     For the Nine-Month Periods
    Ended September 30, 2023
     (Income) Expense (Income) Expense
    Certain Items Impacting Cost of Service, Inclusive of Depreciation:   
    Clinical optimization and reorganization costs$282  $396
    Certain Items Impacting General and Administrative Expenses:   
    Acquisition and integration costs 338   3,106
    CEO transition 1,094   5,279
    Merger-related expenses 4,980   25,151
    Clinical optimization and reorganization costs 466   4,203
    Personal care divestiture    525
    Certain Items Impacting Total Other Income (Expense):   
    Other (income) expense, net (includes $106,000 merger termination fee) (353)  101,838
    Total$6,807  $140,498
    Net of tax$6,242  $138,884
    Diluted EPS$0.19  $4.25


     For the Three-Month Periods
    Ended September 30, 2022
     For the Nine-Month Periods
    Ended September 30, 2022
     (Income) Expense (Income) Expense
    Certain Items Impacting Net Service Revenue:   
    Contingency accrual$931  $9,305 
    Certain Items Impacting Cost of Service:   
    COVID-19 costs 1,701   7,237 
    Clinical optimization and reorganization costs 1,154   1,349 
    Fuel supplement 1,962   3,315 
    Integration costs 311   1,712 
    Certain Items Impacting General and Administrative Expenses:   
    Acquisition and integration costs 3,154   9,855 
    COVID-19 costs 159   396 
    CEO transition    3,500 
    Legal fees - non-routine    241 
    Clinical optimization and reorganization costs 2,676   3,545 
    Legal settlement    (1,058)
    Fuel supplement 218   218 
    Investment impairment 3,009   3,009 
    Certain Items Impacting Total Other Income (Expense):   
    Interest component of certain items (207)  4,445 
    Other expense, net 793   3,851 
    Total$15,861  $50,920 
    Net of tax$11,740  $38,587 
    Diluted EPS$0.36  $1.18 


    (2)Adjusted EBITDA is defined as net income (loss) attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
    (3)Adjusted net service revenue is defined as net service revenue excluding certain items as described in footnote 1.
    (4)Adjusted net income attributable to Amedisys, Inc. is defined as net income (loss) attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
    (5)Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
    (6)Adjusted EBITDA, adjusted net service revenue, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

       

     


    Primary Logo

分享